Chemotherapy-induced Nausea and Vomiting
📧 Sign up to get email alerts when something new happens for Chemotherapy-induced Nausea and Vomiting.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2014-12-20FDA Approved: ONDANSETRON — Supplemental Application (West-Ward Pharmaceuticals Corp)
The FDA approved a supplemental application for ondansetron from West-Ward Pharmaceuticals Corp. (ANDA076780), indicating approval related t…
-
FDA approval · 2014-12-10FDA Approved: ONDANSETRON — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for ondansetron by Hikma Pharmaceuticals USA Inc., enabling a generic version of the antiemetic to b…
-
FDA approval · 2014-12-10FDA Approved: METOCLOPRAMIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for metoclopramide from Teva Pharmaceuticals USA, Inc., authorizing changes to the product's labelin…
-
FDA approval · 2014-12-08FDA Approved: ONDANSETRON — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for ondansetron hydrochloride by Fresenius Kabi USA, LLC under an ANDA, allowing continued manufactu…
-
FDA approval · 2014-12-08FDA Approved: ONDANSETRON — Supplemental Application (AvKARE)
FDA approved a supplemental application for ondansetron from AvKARE, indicating a regulatory update to this product. The approval confirms c…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2014-12-08FDA Approved: ONDANSETRON — Supplemental Application (NorthStar Rx LLC)
The FDA approved a supplemental application for ondansetron hydrochloride (ANDA) filed by NorthStar Rx LLC.
-
FDA approval · 2014-12-08FDA Approved: ONDANSETRON — Supplemental Application (Fresenius Kabi USA, LLC)
The FDA approved a supplemental application for ondansetron hydrochloride (generic) from Fresenius Kabi USA, LLC. This action relates to the…
-
CLINICAL_TRIALS trial_result · 2014-11-26Clinical Trial Update: An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting [Phase 3]
Phase 3 trial evaluating the efficacy and safety of an oral netupitant and palonosetron combination for prevention of chemotherapy-induced n…
-
CLINICAL_TRIALS trial_result · 2014-11-18Clinical Trial Update: A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134) [Phase 1]
Phase 1 pediatric trial of aprepitant (MK-0869) and fosaprepitant (MK-0517) in chemotherapy-induced nausea and vomiting; study terminated wi…
-
CLINICAL_TRIALS trial_result · 2014-11-17Clinical Trial Update: An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting [Phase 3]
Phase 3 trial update evaluating oral and IV palonosetron for prevention of chemotherapy-induced nausea and vomiting; results posted after co…
-
CLINICAL_TRIALS trial_result · 2014-11-17Clinical Trial Update: A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting [Phase 3]
Phase 3 safety study evaluating the oral netupitant/palonosetron combination for preventing chemotherapy-induced nausea and vomiting has com…
-
CLINICAL_TRIALS trial_result · 2014-10-29Clinical Trial Update: Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030) [Phase 2]
Phase 2 trial of fosaprepitant (MK-0517, EMEND IV) in salvage treatment for chemotherapy-induced nausea and vomiting was terminated; results…
-
FDA approval · 2014-10-17FDA Approved: GRANISETRON HYDROCHLORIDE — Supplemental Application (Natco Pharma Limited)
The FDA approved a supplemental application for granisetron hydrochloride submitted by Natco Pharma Limited, updating the approved generic p…
-
FDA approval · 2014-10-10FDA Approved: AKYNZEO — Original Application (Helsinn Therapeutics (U.S.), Inc.)
FDA approved AKYNZEO (netupitant and palonosetron) through an original application (NDA205718) for the prevention of chemotherapy-induced na…
-
FDA approval · 2014-09-18FDA Approved: GRANISETRON — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for granisetron hydrochloride (granisetron) by Fresenius Kabi USA, LLC to update the labeling.
-
FDA approval · 2014-09-18FDA Approved: SANCUSO — Supplemental Application (Cumberland Pharmaceuticals Inc.)
The FDA approved Cumberland Pharmaceuticals' supplemental application for SANCUSO (granisetron), a formulation used to prevent chemotherapy-…
-
FDA approval · 2014-09-18FDA Approved: PALONOSETRON HYDROCHLORIDE — Supplemental Application (Cipla USA Inc.)
The FDA approved a supplemental application for Palonosetron hydrochloride submitted by Cipla USA Inc. under NDA 021372. This action updates…
-
FDA approval · 2014-09-18FDA Approved: GRANISETRON HYDROCHLORIDE — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for granisetron hydrochloride by Mylan Institutional LLC under an ANDA.
-
FDA approval · 2014-09-18FDA Approved: GRANISETRON HYDROCHLORIDE — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for granisetron hydrochloride (Mylan Institutional LLC) under an ANDA.
-
FDA approval · 2014-09-15FDA Approved: GRANISETRON HYDROCHLORIDE — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for granisetron hydrochloride from Mylan Institutional LLC.
-
FDA approval · 2014-09-14FDA Approved: GRANISETRON HYDROCHLORIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved Hikma Pharmaceuticals USA Inc.'s supplemental application for Granisetron hydrochloride (generic antiemetic) under ANDA 078…
-
FDA approval · 2014-09-08FDA Approved: ONDANSETRON — Original Application (Qilu Pharmaceutical Co., Ltd.)
FDA approves the original application for ondansetron from Qilu Pharmaceutical Co., Ltd., enabling the generic product to enter the market.
-
FDA approval · 2014-08-12FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for EMEND (aprepitant) submitted by Merck Sharp & Dohme LLC.
-
CLINICAL_TRIALS trial_result · 2014-08-05Clinical Trial Update: Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097) [Phase 3]
Aprepitant (MK-0869) completed a Phase 3 trial evaluating its effectiveness in preventing chemotherapy-induced nausea and vomiting in adoles…
-
CLINICAL_TRIALS trial_result · 2014-07-28Clinical Trial Update: Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients [Phase 3]
A Phase 3 trial evaluating intravenous palonosetron for prevention of chemotherapy-induced nausea and vomiting in pediatric patients has com…